Penn Pharmaceutical Services Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Penn Pharmaceutical Services Limited - overview
Established
1979
Location
-, -, UK
Primary Industry
Pharmaceuticals
About
Based in the UK and founded in 1979, Penn Pharmaceutical Services Limited operates as a pharmaceutical company. In July 2014, Packaging Coordinators, Inc a portfolio company of Frazier Healthcare Ventures, acquired Penn Pharmaceutical Services Limited for GBP 127 million. As of 2014, the company’s CEO is Richard Yarwood and it employs around 300 employees. Penn Pharmaceutical provides pharmaceutical support services including clinical trial supply, pharmaceutical dosage forms, and manufacturing services for other healthcare organizations to help in their drug development cycle.
The company’s offerings include contained manufacturing, tablet compression, encapsulation, and bottle filling. Penn Pharmaceutical also provides refrigerated warehousing and logistical support services for medicinal products of outside European companies.
Current Investors
Frazier Healthcare Partners, PCI Pharma Services
Primary Industry
Pharmaceuticals
Sub Industries
Business Support Services, Pharmaceuticals, Bottling, Logistics & Distribution, Packaging
Website
www.pennpharm.co.uk
Verticals
Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Penn Pharmaceutical Services Limited - financials
| Fiscal Year Ended | Mar 31, 2009 | Mar 31, 2010 | Mar 31, 2011 | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Sep 30, 2015 | Sep 30, 2016 | Sep 30, 2017 | Sep 30, 2018 | Sep 30, 2019 | Sep 30, 2020 | Sep 30, 2021 | Sep 30, 2022 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 26,679,000 | 26,365,000 | 26,243,000 | 26,892,000 | 46,784,000 | 35,117,000 | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | (1.2%) | (0.5%) | 2.5% | 74.0% | (24.9%) | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | 8,892,000 | 6,645,000 | 7,840,000 | 7,015,000 | 7,672,000 | 8,859,000 | (30,000) | (290,000) | (454,000) | (6,137,000) | 846,000 | - | - | - | - |
| Operating Income (USD) | 5,338,000 | 2,931,000 | 3,870,000 | 2,926,000 | 3,656,000 | 4,290,000 | (30,000) | (290,000) | (454,000) | (6,137,000) | 846,000 | - | - | - | - |
| Operating Margin | 20.0% | 11.1% | 14.7% | 10.9% | 7.8% | 12.2% | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | 33.3% | 25.2% | 29.9% | 26.1% | 16.4% | 25.2% | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (1,916,000) | (2,846,000) | (2,095,000) | (2,970,000) | (2,537,000) | (2,119,000) | (901,000) | (6,176,000) | (1,764,000) | (7,513,000) | 2,206,000 | (2,093,000) | - | - | - |
| % Net Margin | (7.2%) | (10.8%) | (8.0%) | (11.0%) | (5.4%) | (6.0%) | - | - | - | - | - | - | - | - | - |
Penn Pharmaceutical Services Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Penn Pharmaceutical Services Limited | - | ||||||||
| Secondary Buyout | Completed | Penn Pharmaceutical Services Limited | - | ||||||||
| Trade Sale | Completed | Penn Pharmaceutical Services Limited | - | ||||||||
| Buyout | Completed | Penn Pharmaceutical Services Limited | - |
Displaying 1 - 4 of 4
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.